当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

The Clinical Impact of Molecular Techniques to Differentiate Cancer Cells from Healthy Cells

Richard Steensma

The use of molecular methods in diagnostic histopathology has grown increasingly important [1]. They have been quite effective in treating sarcomas in both soft tissue and bone [2]. The employment of auxiliary molecular diagnostic methods is very beneficial because sarcomas are relatively uncommon and difficult to diagnose [3]. Due to the findings of earlier and continuing studies, it is also discovered that particular genetic variations are closely connected with a variety of different mesenchymal lesions. Better illness definition, which results in more accurate diagnostics, the discovery of molecular predictive and prognostic markers, the unravelling of novel molecular targets for more focused treatment approaches, and ultimately drug development are all made possible by molecular techniques [4]. When choosing the appropriate materials for these analyses, the pathologist plays a significant role [5]. Selecting the most appropriate technology for the problems at hand, and 3. Combining the findings of these analyses with the clinic pathological characteristics to arrive at a definitive diagnosis. Here, we examine the main uses of this strategy and analyse its benefits and drawbacks [6]. The uses of molecular methods for soft and bone tumours will be the main emphasis of this review. Molecular methods are frequently used in pathology to study nucleic acids, such as RNA and DNA, using hybridization on a cut slide or polymerase chain reaction methods on isolated DNA or RNA for example, reverse transcriptase PCR, quantitative PCR [7]. A pathologist is essential to correctly leading these analyses. In particular: Only one suitable material should be chosen, with an acceptable quantity of important lesional tissue A diverse collection of tumours, primary soft tissue and bone lesions include benign and malignant lesions [8].

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません。